Endogenous fibrinolysis: An important mediator of thrombus formation and cardiovascular risk

Journal of the American College of Cardiology

Volumn 65, Issue 16, 2015, Pages 1683-1699

  Okafor, Osita N ^a   Gorog, Diana A ^a,b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

atherosclerosis; platelet activation; platelet aggregation; platelet function tests; thrombolysis; thrombosis

Indexed keywords

BETA GLOBULIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; PAI 1 GENE; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; THROMBOTEST; BLOOD; CARDIOVASCULAR DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOSIS;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FIBRINOLYSIS; HUMANS; THROMBELASTOGRAPHY; THROMBOSIS;

EID: 84928019142     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.02.040     Document Type: Review

References (124)

1. V. Fuster, P.R. Moreno, and Z.A. Fayad et al. Atherothrombosis and high-risk plaque: part I: evolving concepts J Am Coll Cardiol 46 2005 937 954
2. S. Penz, A.J. Reininger, and R. Brandi et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI FASEB J 19 2005 898 909
3. A.J. Reininger, I. Bernlochner, and S.M. Penz et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques J Am Coll Cardiol 55 2010 1147 1158
4. E. Cambruzzi, J.C. Sebben, and R. Budzyn et al. Histopathological evaluation of coronary thrombi in patients with ST-segment elevation myocardial infarction Revista Brasileira de Cardiologia Invasiva 20 2012 267 273
5. S.Z. Rittersma, A.C. van der Wal, and K.T. Koch et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention Circulation 111 2005 1160 1165
6. N.J. Verouden, M.C. Kramer, and X. Li et al. Histopathology of aspirated thrombus and its association with ST-segment recovery in patients undergoing primary percutaneous coronary intervention with routine thrombus aspiration Catheter Cardiovasc Interv 77 2011 35 42
7. M.C. Kramer, A.C. van der Wal, and K.T. Koch et al. Histopathological features of aspirated thrombi after percutaneous coronary intervention in patients with ST-elevation myocardial infarction PLoS One 4 2009 e5817
8. G.R. Henriques de, A.C. van der Wal, and C.M. van der Loos et al. Sudden unexpected death in young adults. Discrepancies between initiation of acute plaque complications and the onset of acute coronary death Eur Heart J 23 2002 1433 1440
9. H.J. Swan Thrombolysis in acute myocardial infarction: treatment of the underlying coronary artery disease Circulation 66 1982 914 916
10. K.R. Bainey, Y. Fu, and G.S. Wagner et al. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments Am Heart J 156 2008 248 255
11. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial Lancet 367 2006 569 578
12. P. Fefer, H. Hod, H. Hammerman for the Acute Coronary Syndrome Israeli Survey (ACSIS) 2006 Study Group Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction Am J Cardiol 103 2009 149 153
13. J. Mann, and M.J. Davies Mechanisms of progression in native coronary artery disease: role of healed plaque disruption Heart 82 1999 265 268
14. A.P. Burke, F.D. Kolodgie, and A. Farb et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression Circulation 103 2001 934 940
15. R. Varin, S. Mirshahi, and P. Mirshahi et al. Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban Thromb Res 131 2013 e100 e109
16. I.K. Jang, H.K. Gold, and A.A. Ziskind et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis Circulation 79 1989 920 928
17. Y. Zhu, P. Carmeliet, and W.P. Fay Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance Circulation 99 1999 3050 3055
18. A. Undas Fibrin clot properties and their modulation in thrombotic disorders Thromb Haemost 112 2014 32 42
19. T.Z. Dhall, G.A. Shah, and I.A. Ferguson et al. Fibrin network structure: modification by platelets Thromb Haemost 49 1983 42 46
20. J.L. Mitchell, A.S. Lionikiene, and S.R. Fraser et al. Functional factor XIII-A is exposed on stimulated platelet surface Blood 124 2014 3982 3990
21. G. Dickneite, H. Herwald, and W. Korte et al. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions Thromb Haemost 113 2015 686 697
22. E.L. Hethershaw, A.L. Cilia La Corte, and C. Duval et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis J Thromb Haemost 12 2014 197 205
23. N.J. Mutch, J.S. Koikkalainen, and S.R. Fraser et al. Model thrombi formed under flow reveal the role of factor-XIII- mediated cross-linking in resistance to fibrinolysis J Thromb Haemost 8 2010 2017 2024
24. R.P. Kreutz, A. Bitar, and J. Owens et al. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease J Thromb Thrombolysis 38 2014 380 387
25. M. May, D.A. Lawlor, and R. Patel et al. Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study Eur J Cardiovasc Prev Rehabil 14 2007 638 645
26. A.D. Pradhan, A.Z. LaCroix, and R.D. Langer et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women Circulation 110 2004 292 300
27. F.B. Smith, F.G. Fowkes, and A. Rumley et al. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study Eur Heart J 21 2000 1607 1613
28. S. Kinlay, G.G. Schwartz, and A.G. Olsson et al. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study Atherosclerosis 206 2009 551 555
29. C.W. Lee, J.M. Ahn, and D.W. Park et al. Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty Atherosclerosis 196 2008 327 332
30. T. Soeki, Y. Tamura, and H. Shinohara et al. Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death Int J Cardiol 85 2002 277 283
31. D.A. Gorog Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease J Am Coll Cardiol 55 2010 2701 2709
32. R. Marcucci, D. Brogi, and F. Sofi et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting Heart 92 2006 377 381
33. G.D. Lowe, J. Danesh, and S. Lewington et al. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis Eur Heart J 25 2004 252 259
34. A.R. Folsom, N. Aleksic, and E. Park et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb Vasc Biol 21 2001 611 617
35. E. Kowalski, M. Kopeć, and S. Niewiarowski An evaluation of the euglobulin method for the determination of fibrinolysis J Clin Pathol 12 1959 215 218
36. A.A. Smith, L.J. Jacobson, and B.I. Miller et al. A new euglobulin clot lysis assay for global fibrinolysis Thromb Res 112 2003 329 337
37. R.J. Luddington Thrombelastography/thromboelastometry Clin Lab Haematol 27 2005 81 90
38. D.J. Perry, D.A. Fitzmaurice, and S. Kitchen et al. Point-of-care testing in haemostasis Br J Haematol 150 2010 501 514
39. V.A. Bowbrick, D.P. Mikhailidis, and G. Stansby Value of thromboelastography in the assessment of platelet function Clin Appl Thromb Hemost 9 2003 137 142
40. S.C. Kettner, O.P. Panzer, and S.A. Kozek et al. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery Anesth Analg 89 1999 580 584
41. K.J. Tuman, R.J. McCarthy, and M. Djuric et al. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay J Cardiothorac Vasc Anesth 8 1994 144 149
42. A. Levrat, A. Gros, and L. Rugeri et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients Br J Anaesth 100 2008 792 797
43. G.F. Genet, S.R. Ostrowski, and A.M. Sorensen et al. Detection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals Clin Appl Thromb Hemost 18 2012 638 644
44. J.L. Kashuk, E.E. Moore, and M. Sawyer et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma Ann Surg 252 2010 434 442 discussion 443-4
45. D. Dirkmann, J. Radu-Berlemann, and K. Gorlinger et al. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid J Trauma Acute Care Surg 74 2013 482 488
46. M.S. Avidan, J. Da Fonseca, and K. Parmar et al. The effects of aprotinin on thromboelastography with three different activators Anesthesiology 95 2001 1169 1174
47. A. Zambruni, U. Thalheimer, and G. Leandro et al. Thromboelastography with citrated blood: comparability with native blood, stability of citrate storage and effect of repeated sampling Blood Coagul Fibrinolysis 15 2004 103 107
48. E. Pretorius, H.M. Oberholzer, and W.J. van der Spuy et al. Comparing techniques: the use of recalcified plasma in comparison with citrated plasma alone and in combination with thrombin in ultrastructural studies Hematology 16 2011 337 340
49. S. Rajwal, M. Richards, and M. O'Meara The use of recalcified citrated whole blood-a pragmatic approach for thromboelastography in children Paediatr Anaesth 14 2004 656 660
50. M. Wasowicz, C. Srinivas, and M. Meineri et al. Technical report: analysis of citrated blood with thromboelastography: comparison with fresh blood samples Can J Anaesth 55 2008 284 289
51. U. Thalheimer, C.K. Triantos, and D.N. Samonakis et al. A comparison of kaolin-activated versus nonkaolin-activated thromboelastography in native and citrated blood Blood Coagul Fibrinolysis 19 2008 495 501
52. V. Jeger, H. Zimmermann, and A.K. Exadaktylos Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries? J Trauma 66 2009 1253 1257
53. M. Chitlur, B. Sorensen, and G.E. Rivard et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group Haemophilia 17 2011 532 537
54. D.P. Kitchen, S. Kitchen, and I. Jennings et al. Quality assurance and quality control of thrombelastography and rotational thromboelastometry: the UK NEQAS for blood coagulation experience Semin Thromb Hemost 36 2010 757 763
55. Y. Dai, A. Lee, and L.A. Critchley et al. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature Anesth Analg 108 2009 734 742
56. J. Yamamoto, T. Yamashita, and H. Ikarugi et al. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis Blood Coagul Fibrinolysis 14 2003 31 39
57. J. Yamamoto, N. Inoue, and K. Otsui et al. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential Thromb Res 133 2014 919 926
58. D.L. Bark Jr., and D.N. Ku Wall shear over high degree stenoses pertinent to atherothrombosis J Biomech 43 2010 2970 2977
59. M.J. Maxwell, E. Westein, and W.S. Nesbitt et al. Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation Blood 109 2007 566 576
60. S. Sharma, K. Farrington, and R. Kozarski et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease Euro Heart J 34 2013 354 363
61. S. Saraf, C. Christopoulos, and I.B. Salha et al. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction J Am Coll Cardiol 55 2010 2107 2115
62. I. Isordia-Salas, A. Leaños-Miranda, and I.M. Sainz et al. Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients Rev Esp Cardiol 62 2009 365 372
63. O. Onalan, G. Balta, and A. Oto et al. Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease J Thromb Thrombolysis 26 2008 211 217
64. A. Smith, C. Patterson, and J. Yarnell et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study Circulation 112 2005 3080 3087
65. K. Takazoe, H. Ogawa, and H. Yasue et al. Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris Ann Med 33 2001 206 212
66. T.J. Wang, P. Gona, and M.G. Larson et al. Multiple biomarkers for the prediction of first major cardiovascular events and death N Engl J Med 355 2006 2631 2639
67. P.F. Marx, T. Plug, and S.R. Havik et al. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J Thromb Haemost 7 2009 445 452
68. J.P. Collet, Y. Allali, and C. Lesty et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis Arterioscler Thromb Vasc Biol 26 2006 2567 2573
69. E.T. Bach-Gansmo, S. Halvorsen, and H.C. Godal et al. D-dimers are degraded by human neutrophil elastase Thromb Res 82 1996 177 186
70. F. Semeraro, C.T. Ammollo, and N. Semeraro et al. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins Haematologica 94 2009 819 826
71. S.R. Torr-Brown, and B.E. Sobel Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets Thromb Res 72 1993 413 421
72. A.J. Simpson, N.A. Booth, and N.R. Moore et al. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease Br J Haematol 75 1990 543 548
73. T. Soeki, Y. Tamura, and N. Fukuda et al. Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction Jpn Circ J 64 2000 547 553
74. K.M. Katsaros, S.P. Kastl, and K. Huber et al. Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation Thromb Res 123 2008 79 84
75. A. Suehiro, I. Wakabayashi, and T. Yamashita et al. Attenuation of spontaneous thrombolytic activity measured by the global thrombosis test in male habitual smokers J Thromb Thrombolysis 37 2014 414 418
76. H. Ikarugi, T. Yamashita, and R. Aoki et al. Impaired spontaneous thrombolytic activity in elderly and in habitual smokers, as measured by a new global thrombosis test Blood Coagul Fibrinolysis 14 2003 781 784
77. A. Suehiro, I. Wakabayashi, and K. Uchida et al. Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome Thromb Res 129 2012 499 501
78. A.S. Levey, J.A. Beto, and B.E. Coranado et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 1998 853 906
79. A. Sagripanti, A. Cupisti, and U. Baicchi et al. Plasma parameters of the prothrombotic state in chronic uremia Nephron 63 1993 273 278
80. R. Davenport, and S. Khan Management of major trauma haemorrhage: treatment priorities and controversies Br J Haematol 155 2011 537 548
81. C.G. Krenn, and A.M. De Wolf Current approach to intraoperative monitoring in liver transplantation Curr Opin Organ Transplant 13 2008 285 290
82. L. Shore-Lesserson, H.E. Manspeizer, and M. DePerio et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery Anesth Analg 88 1999 312 319
83. O. Onwuemene, D. Green, and L. Keith Postpartum hemorrhage management in 2012: predicting the future Int J Gynaecol Obstet 119 2012 3 5
84. D. MacIvor, A. Rebel, and Z.U. Hassan How do we integrate thromboelastography with perioperative transfusion management? Transfusion 53 2013 1386 1392
85. R. Davenport Pathogenesis of acute traumatic coagulopathy Transfusion 53 Suppl 1 2013 23S 27S
86. D. Royston, and S. von Kier Reduced haemostatic factor transfusion using heparinase-modified thromboelastography during cardiopulmonary bypass Br J Anaesth 86 2001 575 578
87. S. Khurana, J.C. Mattson, and S. Westley et al. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography J Lab Clin Med 130 1997 401 411
88. A.R. Hobson, G.W. Petley, and K.D. Dawkins et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography Platelets 18 2007 497 505
89. T. Lang, A. Bauters, and S.L. Braun et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry Blood Coagul Fibrinolysis 16 2005 301 310
90. A. Kupesiz, M. Rajpurkar, and I. Warrier et al. Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography Blood Coagul Fibrinolysis 21 2010 320 324
91. P. Willeit, A. Thompson, and T. Aspelund et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses PloS One 8 2013 e55175
92. S.G. Wannamethee, P.H. Whincup, and A.G. Shaper et al. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men J Thromb Haemost 7 2009 1605 1611
93. K.L. Chien, H.C. Hsu, and T.C. Su et al. Lipoprotein(a) and cardiovascular disease in ethnic Chinese: the Chin-Shan Community Cardiovascular Cohort Study Clin Chem 54 2008 285 291
94. D. Gurdasani, B. Sjouke, and S. Tsimikas et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study Arterioscler Thromb Vasc Biol 32 2012 3058 3065
95. P.J. Nestel, E.H. Barnes, and A.M. Tonkin et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease Aterioscler Thromb Vasc Biol 33 2013 2902 2908
96. S.W. Kwon, J.Y. Kim, and J.M. Sung et al. Elevated lipoprotein(a) has incremental prognostic value in Type 2 Diabetic patients with symptomatic coronary artery disease J Atheroscler Thrombo 2014 Nov 29 [E-pub ahead of print]
97. S.W. Kwon, B.K. Lee, and B.K. Hong et al. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients Int J Cardiol 167 2013 1990 1994
98. G. Rosser, P. Tricoci, and D. Morrow et al. PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease J Thromb Thrombolysis 38 2014 423 429
99. K. Taomoto, H. Ohnishi, and Y. Kuga et al. Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test Pathophysiol Haemost Thromb 37 2010 43 48
100. F. Canoui-Poitrine, G. Luc, and J.M. Bard et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study Cerebrovasc Dis 30 2010 252 259
101. S.S. Virani, A. Brautbar, and B.C. Davis et al. Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study Circulation 125 2012 241 249
102. M.L. O'Donoghue, D.A. Morrow, and S. Tsimikas et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease J Am Coll Cardiol 63 2014 520 527
103. J. Suk Danik, N. Rifai, and J.E. Buring et al. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women JAMA 296 2006 1363 1370
104. P.R. Kamstrup, M. Benn, and A. Tybjaerg-Hansen et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study Circulation 117 2008 176 184
105. M.G. Shilpak, J.A. Simon, and E. Vittinghoff et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause JAMA 283 2000 1845 1852
106. P. Zamani, C.G. Schwartz, A.G. Olsson for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study J Am Heart Assoc 2 2013 e003103
107. A. Nordenhem, K. Leander, and J. Hallqvist et al. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project Thromb Res 116 2005 223 232
108. M. Cushman, R.N. Lemaitre, and L.H. Kuller et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study Arterioscler Thromb Vasc Biol 19 1999 493 498
109. P.E. Morange, C. Bickel, and V. Nicaud et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study Arterioscler Thromb Vasc Biol 26 2006 2793 2799
110. D.A. Tregouet, R. Schnabel, M.C. Alessi for the AtheroGene Investigators Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study J Thromb Haemost 7 2009 49 57
111. A. Gaw, H.M. Murray, E.A. Brown for the PROSPER Study Group Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER) Atherosclerosis 180 2005 381 388
112. A. Bennet, E. Di Angelantonio, and S. Ergou et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data Arch Intern Med 168 2008 598 608
113. Y.H. Jeong, K.P. Bliden, and A.R. Shuldiner et al. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes Thromb Haemost 111 2014 713 724
114. P.A. Gurbel, K.P. Bliden, and I.A. Navickas et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 160 2010 346 354
115. F.K. Tang, L.J. Lin, and N. Hua et al. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention Chin Med J (Engl) 125 2012 631 638
116. P.A. Gurbel, K.P. Bliden, and R.P. Kreutz et al. The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20 2009 97 104
117. P.A. Gurbel, K.P. Bliden, and K. Guyer et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
118. K.P. Bliden, J. DiChiara, and U.S. Tantry et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary interventionis the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666
119. P.A. Gurbel, K.P. Bliden, and E. Cohen et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 19 2008 268 275
120. X.F. Tang, J.H. Zhang, and J. Wang et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention Chin Med J (Engl) 126 2013 1069 1075
121. H. Wu, J. Qian, and A. Sun et al. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment Circ J 76 2012 2773 2778
122. J. Cao, L. Liu, and L. Fan et al. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease Aging Male 15 2012 140 147
123. X.F. Tang, J. Wang, and J.H. Zhang et al. Effect of the CYP2C19∗2 and∗3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention Eur J Clin Pharmacol 69 2013 1103 1112
124. N.P. Dridi, J.T. Lønborg, and M.D. Radu et al. Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary intervention Clin Appl Thromb Hemost 20 2013 825 831